Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma A Secondary Analysis of a Randomized Clinical Trial

被引:4
作者
Sunkara, Pranit R. [1 ]
Graff, Justin T. [1 ]
Cramer, John D. [1 ,2 ]
机构
[1] Wayne State Univ, Dept Otolaryngol Head & Neck Surg, Detroit, MI USA
[2] Wayne State Univ, Dept Otolaryngol Head & Neck Surg, 4201 St Antoine,UHC 5E, Detroit, MI 48201 USA
关键词
LOCAL RECURRENCE; SURGERY; CHEMOTHERAPY;
D O I
10.1001/jamaoto.2022.5186
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
IMPORTANCE Clear surgical margins reduce the risk of local recurrence, improve survival, and determine decision-making with regard to adjuvant treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the definitions of clear, close, or positive surgical margins vary in both the literature and in practice.Objective To examine whether the association between surgical margin distance and survival varies by primary tumor site.Design, Setting, and Participants This was a secondary analysis of a multi-institutional, multinational randomized clinical trial. The trial enrolled patients from January 22, 2007, to March 29, 2013, with stage II to IVA resected SCCHN with extranodal extension (ENE) or positive margins (< 5 mm from invasive tumor to the resected margin). The current analysis included those patients with known ENE and margin status and was conducted from April 29, 2022, to December 19, 2022.Interventions Patients received adjuvant chemoradiotherapy plus either placebo or lapatinib.Main Outcomes and Measures Overall survival (OS) was calculated to examine association with surgical margin distance, primary site, and survival, with stratification by ENE status.Results Among 688 patients enrolled in the trial, 630 patients with known ENE and margin status were included. Exact patient ages were not made available; 523 (83%) patients were male, and 415 (66%) patients were White. Patients with 1 high-risk feature (positive margins or ENE) had significantly better OS vs 2 high-risk features (hazard ratio [HR], 0.65; 95% CI, 0.49-0.87), although most other results were not statistically significant. For example, in the cohort with ENE-negative disease, multivariable adjusted analysis showed nonsignificant improvements with shorter surgical margin distance (1- to 5-mm margins), and no association with OS was found in the cohort with ENE-positive status (either > 5 mm margins or 1-5 mm margins). The association between survival and margin distance varied based on primary site, human papillomavirus (HPV) status, and ENE status. For example, HPV-positive status was associated with a significant and clinically meaningful increase in survival (adjusted HR, 0.33; 95% CI, 0.11-0.97). The improvement was greatest, although not significantly so, in patients with ENE- and HPV-negative oropharynx (OP), hypopharynx (HP), and larynx cancer (HR, 0.57; 95% CI, 0.30-1.10). No survival benefit was seen in ENE-negative oral cavity cancer (HR, 0.89; 95% CI, 0.45-1.77), nor was an association observed between margins and OS in HPV-positive OP cancer.Conclusions and Relevance In this secondary analysis of a randomized clinical trial, the presence of high-risk features (extranodal extension, positive margins, or both) was associated with worse survival; longer survival was observed with greater surgical margin distance among patients with oral cavity tumors and human papillomavirus-negative tumors of the OP, larynx, or HP. No other significant differences were found. These findings support variable interpretation of surgical margin distance based on the primary site and HPV status.
引用
收藏
页码:317 / 326
页数:10
相关论文
共 50 条
  • [41] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [42] Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN
    Jonas, Hanna
    Simnica, Donjete
    Bussmann, Lara
    Zech, Henrike
    Doescher, Johannes
    Laban, Simon
    Busch, Chia-Jung
    Binder, Mascha
    ORAL ONCOLOGY, 2022, 126
  • [43] Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma A Randomized Clinical Trial
    Siu, Lillian L.
    Waldron, John N.
    Chen, Bingshu E.
    Winquist, Eric
    Wright, Jim R.
    Nabid, Abdenour
    Hay, John H.
    Ringash, Jolie
    Liu, Geoffrey
    Johnson, Ana
    Shenouda, George
    Chasen, Martin
    Pearce, Andrew
    Butler, James B.
    Breen, Stephen
    Chen, Eric Xueyu
    FitzGerald, T. J.
    Childs, T. J.
    Montenegro, Alexander
    O'Sullivan, Brian
    Parulekar, Wendy R.
    JAMA ONCOLOGY, 2017, 3 (02) : 220 - 226
  • [44] Diagnostic accuracy of intraoperative margin assessment techniques in surgery for head and neck squamous cell carcinoma: A meta-analysis
    Higginson, James A.
    Breik, Omar
    Thompson, Alexandra H.
    Ashrafian, Hutan
    Hardman, John C.
    Takats, Zoltan
    Paleri, Vinidh
    Dhanda, Jagtar
    ORAL ONCOLOGY, 2023, 142
  • [45] Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) - A phase 3 randomized controlled trial
    Mallick, Supriya
    Dagar, Abhilash
    Ghosh, Adrija
    Aashita
    Raj, Jaswin
    Hazarika, Sangeeta
    Meena, Jitendra K.
    Kumar, Akash
    Sharma, Jyoti
    Panda, Smriti
    Sharma, Aman
    Singh, Mayank
    Sharma, Dayanand
    Thakar, Alok
    RADIOTHERAPY AND ONCOLOGY, 2025, 202
  • [46] Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma
    Mastrolonardo, Eric V.
    Llerena, Pablo
    Lu, Joseph
    Nunes, Kathryn
    Choi, Grace K.
    Amin, Dev
    Bridgham, Kelly M.
    Campbell, Daniel
    Philips, Ramez
    Cognetti, David M.
    Luginbuhl, Adam J.
    Curry, Joseph M.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2024, : 688 - 694
  • [47] Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma
    Chen, Jin-Hua
    Yen, Yu-Chun
    Chen, Tsung-Ming
    Yuan, Kevin Sheng-Po
    Lee, Fei-Peng
    Lin, Kuan-Chou
    Lai, Ming-Tang
    Wu, Chia-Che
    Chang, Chia-Lun
    Wu, Szu-Yuan
    CANCER MEDICINE, 2017, 6 (01): : 142 - 153
  • [48] How Does the Close Surgical Margin Impact Recurrence and Survival When Treating Oral Squamous Cell Carcinoma?
    Dillon, Jasjit K.
    Brown, Christopher B.
    McDonald, Tyler M.
    Ludwig, David C.
    Clark, Patrick J.
    Leroux, Brian G.
    Futran, Neal D.
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2015, 73 (06) : 1182 - 1188
  • [49] Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma
    Becherini, Carlotta
    Banini, Marco
    Desideri, Isacco
    Salvestrini, Viola
    Caprara, Luisa
    Scotti, Vieri
    Ganovelli, Michele
    Morelli, Ilaria
    Romei, Andrea
    Livi, Lorenzo
    Bonomo, Pierluigi
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
  • [50] Positive frozen section margins predict local recurrence in R0-resected squamous cell carcinoma of the head and neck
    Ettl, Tobias
    El-Gindi, Alain
    Hautmann, Matthias
    Gosau, Martin
    Weber, Florian
    Rohrmeier, Christian
    Gerken, Michael
    Mueller, Steffen
    Reichert, Torsten
    Klingelhoeffer, Christoph
    ORAL ONCOLOGY, 2016, 55 : 17 - 23